Can the Benefits From Biosimilars be Sustainably Increased? Policy Recommendations for Europe, Middle East and Canada

October 19, 2022

Back to all webinars

Open to all ISPOR Members and Non-members

Title: Can the Benefits From Biosimilars Be Sustainably Increased? Policy Recommendations for Europe, Middle East and Canada

Wednesday, October 19, 2022
9:00AM EDT | 1:00PM UTC | 3:00PM CEST

Click here for time zone conversion

Register Here


Biosimilars offer great potential for the patients, payers and the whole society. However, there exist policy barriers which can hinder this potential. The debate will analyze the challenges and opportunities for biosimilars uptake in Europe, Middle East and Canada.


Steven Simoens, MSc, PhD,
Professor of Health Economics, KU Leuven, Leuven, Belgium


John Esdaile, MD, MPH, FRCPC, FCAHS, MACR, Professor, University of British Columbia and University of Calgary, Canada

Pius Gyger, Independent Health Economist, Switzerland

Francesco Saverio Mennini, Aggregate Professor, Tor Vergata, University of Rome, Rome, Italy

Khalid Alnaqbi, Chair of the Emirati Board of Rheumatology, National Institute for Health Specialties, Abu Dhabi, United Arab Emirates

Javier Bécares, Head of Service, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

Beatriz Ardizone Jiménez, MSc, Associate Pharmacist, Hospital University Rey Juan Carlos, Madrid, Spain

Sponsored by: Charles River Associates

Please note:
On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.

Reservations are on a first-come, first-served basis.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now